Business Description
Neurizon Therapeutics Ltd
NAICS : 325412
SIC : 2834
ISIN : AU0000357261
Description
Financial Strength
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.92 | |||||
Debt-to-EBITDA | -0.18 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | 10.92 | |||||
Beneish M-Score | -4.24 | |||||
WACC vs ROIC |
Growth Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -6.5 | |||||
3-Year EBITDA Growth Rate | -81.7 | |||||
3-Year EPS without NRI Growth Rate | -17 | |||||
3-Year FCF Growth Rate | -7.7 | |||||
3-Year Book Growth Rate | -26.8 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 21.05 | |||||
9-Day RSI | 32.07 | |||||
14-Day RSI | 37.48 | |||||
6-1 Month Momentum % | 20.59 | |||||
12-1 Month Momentum % | 138.37 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 12.42 | |||||
Quick Ratio | 12.42 | |||||
Cash Ratio | 11.97 | |||||
Days Inventory | 483.12 | |||||
Days Sales Outstanding | 26.56 | |||||
Days Payable | 354.35 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -4.8 | |||||
Shareholder Yield % | -13.33 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 72.1 | |||||
Operating Margin % | -131.06 | |||||
Net Margin % | -219.97 | |||||
ROE % | -106.67 | |||||
ROA % | -88.73 | |||||
ROIC % | -292.15 | |||||
ROC (Joel Greenblatt) % | -544.18 | |||||
ROCE % | -88.89 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 19.44 | |||||
PB Ratio | 7.61 | |||||
Price-to-Tangible-Book | 8.75 | |||||
EV-to-EBIT | -12.67 | |||||
EV-to-EBITDA | -12.67 | |||||
EV-to-FCF | -18.71 | |||||
Price-to-Median-PS-Value | 2.92 | |||||
Price-to-Net-Current-Asset-Value | 8.75 | |||||
Price-to-Net-Cash | 8.75 | |||||
Earnings Yield (Greenblatt) % | -7.89 | |||||
FCF Yield % | -6.02 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Neurizon Therapeutics Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil A$) | |||
EPS (TTM) (A$) | -0.021 | ||
Beta | 2.06 | ||
Volatility % | 119.06 | ||
14-Day RSI | 37.48 | ||
14-Day ATR (A$) | 0.010892 | ||
20-Day SMA (A$) | 0.1895 | ||
12-1 Month Momentum % | 138.37 | ||
52-Week Range (A$) | 0.087 - 0.535 | ||
Shares Outstanding (Mil) | 491.71 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 1 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Neurizon Therapeutics Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Neurizon Therapeutics Ltd Stock Events
Event | Date | Price(A$) | ||
---|---|---|---|---|
No Event Data |
Neurizon Therapeutics Ltd Frequently Asked Questions
What is Neurizon Therapeutics Ltd(ASX:NUZ)'s stock price today?
When is next earnings date of Neurizon Therapeutics Ltd(ASX:NUZ)?
Does Neurizon Therapeutics Ltd(ASX:NUZ) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |